Nanoviricides Stock Price, News & Analysis

NanoViricides is progressing towards a Phase II clinical trial of its drug candidate NV-387, aimed at treating multiple viral infections including RSV, COVID, and Influenza. Dr. Anil Diwan is collaborating with experts to develop a trial plan and protocol. NV-387 has demonstrated strong effectiveness in animal studies and could potentially become a first-line treatment for respiratory viral infections, eliminating the need for testing virus types before treatment.

The estimated market size for these infections is over $8 billion in 2024, expected to grow to $12 billion by 2027. The Phase II trial will assess NV-387's effectiveness against multiple viruses in a single study, aiming to reduce costs and enhance return on investment. NV-387 recently completed a Phase I trial, showing good tolerability. The company envisions a new paradigm in treating viral infections, similar to broad-spectrum antibiotics for bacteria.

NanoViricides (NYSE:NNVC) provides an update on its clinical program for NV-387, a broad-spectrum antiviral drug. Key points:

• NV-387 mimics sulfated-proteoglycan features used by over 90% of pathogenic human viruses to infect cells
• Showed superiority or equivalence to existing drugs in animal trials against influenza, COVID, RSV, and orthopoxviruses
• Potential market size of $8 billion in 2024, growing to $12 billion in three years for influenza, RSV, and COVID alone
• Company completing database audit of Phase 1a/1b trial and preparing for Phase II trials
• Developing novel adaptive clinical trial design to evaluate effectiveness against multiple respiratory viruses
• Initiating outreach for big pharma collaborations to speed up programs and provide financing

NanoViricides, Inc. (NYSE American: NNVC) is developing NV-387, a broad-spectrum antiviral drug candidate showing promise against multiple viruses, including COVID-19, RSV, and influenza. The company recently completed a Phase 1 safety study for NV-387, with results expected in the second half of 2024. A Phase 2 clinical trial for RSV is being planned.

Key highlights:

• NV-387 demonstrated 180% improvement in survival compared to Remdesivir's 50% in animal studies
• Oral and injectable formulations developed
• Showed excellent safety and tolerability in Phase 1 human trials
• Potential to address limitations of current COVID-19 treatments
• Broad spectrum activity could represent a new paradigm in viral therapy

NanoViricides, a clinical-stage leader in antiviral nanomedicines, has gained significant attention through two independent research reports. The reports emphasize the broad-spectrum potential of NanoViricides' lead drug candidate, NV-387, which has shown efficacy in preclinical trials against multiple viruses, including RSV, Influenza A, and COVID-19. This compound could disrupt the $3 billion market for antiviral therapies. The company's transition into clinical-stage development and upcoming Phase 1 and 2 trials are key milestones. Analysts highlight the promise of NV-387 as an orally deliverable antiviral medication that could be widely prescribed, marking a potential breakthrough in treating viral respiratory infections.

NanoViricides (NYSE American:NNVC) reminds investors of the strong safety and effectiveness of its lead drug candidate NV-387 against coronaviruses. The company highlights the need for effective COVID-19 treatments, as new variants continue to emerge. Animal studies show NV-387 outperforming remdesivir, with a 180% improvement in survival rates for intravenous treatment and 88% for oral formulation.

NV-387 has completed a Phase I human clinical trial in India, demonstrating excellent safety and tolerability. The drug shows broad antiviral spectrum, potentially effective against coronaviruses, RSV, influenza, and poxviruses. NanoViricides is now seeking collaborations with pharmaceutical companies to advance NV-387 towards regulatory approvals for multiple antiviral indications.

NanoViricides discusses its development of NV-387, a drug targeting multiple respiratory viruses including COVID, RSV, Influenza, and Bird Flu.

NV-387 has shown superior activity in animal models compared to approved drugs and has completed Phase I trials with no adverse events.

The company is planning Phase II trials for RSV and other indications.

NV-387's biomimicry reduces the likelihood of viral escape and offers a cost-effective approach to pandemic preparedness.

Regulatory compliance audits are ongoing as the Phase I trial site closes.

NanoViricides aims to advance NV-387 through the fastest regulatory paths for approval worldwide.

NanoViricides, a leader in antiviral nanomedicines, presents the progress of its drug candidate NV-387, which has completed Phase I clinical trials with no adverse events reported. NV-387 has demonstrated significant efficacy against various viruses, including RSV, Influenza, and coronavirus, in preclinical studies. The company plans to advance NV-387 to Phase II trials, targeting pediatric RSV treatment. NanoViricides estimates a potential market size of $16 billion in three years for diseases NV-387 aims to treat. Additionally, the company is developing NV-HHV-1 for herpesvirus-related conditions and possesses a cGMP-compliant manufacturing facility, supporting its clinical and market entry plans.

NanoViricides has announced that its antiviral candidate NV-387 shows promising results against the H5N1 bird flu virus. This drug demonstrated superiority over existing treatments like Oseltamivir, Peramivir, and Baloxavir in a model of Influenza A/H3N2 infection. NV-387 not only prevents viral and immune damage to the lungs but also targets the viral MBS site, which is common in HPAI H5N1. This adaptability means NV-387 is likely to remain effective despite viral mutations. The increasing spread of H5N1 among mammals and potential for human infection underscores the need for such treatments. NanoViricides is advancing NV-CoV-2 for COVID-19 and other antiviral candidates, although exact clinical trial dates remain uncertain due to dependency on collaborators and consultants.

NanoViricides reports that its antiviral NV-387 has shown efficacy in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model. NV-387, both orally and intravenously, significantly reduced lung cell infiltration and mucus load compared to untreated controls. Oral treatment resulted in 31% lung infiltration, and intravenous treatment showed 22%, against 68% for untreated controls. Similarly, mucus index values were 53 (oral) and 32 (intravenous) versus 138 for untreated controls. NV-387 improved survival by 88%, surpassing the 25%-38% improvement by approved drugs Oseltamivir, Rapivab, and Baloxavir. Phase I clinical trials demonstrated no adverse events, positioning NV-387 for Phase II trials. Furthermore, NV-387’s host-mimetic design minimizes the likelihood of viral resistance, unlike other drugs.